MIST — Milestone Pharmaceuticals Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2019-05-09.
Performance
Technicals
Others in Healthcare
Measured signals that fired on MIST
| date | signal | measured base rate |
|---|---|---|
| 2026-05-07 | Short volume far above its own normal short | -0.76% over 21 days · t = -2.79 · n = 5,897 statistically distinguishable from its control group |
| 2026-04-09 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-04-16 | Oliveto Joseph President and CEO | Open-market sale 10b5-1 plan | 36.5K | 2.26 | 82.5K |
| 2026-01-26 | Oliveto Joseph President and CEO | Open-market sale | 34.5K | 1.93 | 66.6K |
| 2026-01-26 | Bharucha David Chief Medical Officer | Open-market sale | 12.2K | 1.93 | 23.6K |
| 2026-01-26 | Hasija Amit CFO & EVP of Corp. Development | Open-market sale | 12.2K | 1.93 | 23.6K |
| 2026-01-26 | Nelson Jeffrey Edward Chief Operating Officer | Open-market sale | 12.2K | 1.93 | 23.6K |
| 2026-01-26 | Muller Lorenz Chief Commercial Officer | Open-market sale | 11.2K | 1.93 | 21.6K |
| 2026-01-26 | Hasija Amit CFO & EVP of Corp. Development | Option exercise | 20.1K | — | — |
| 2026-01-26 | Bharucha David Chief Medical Officer | Option exercise | 20.1K | — | — |
| 2026-01-26 | Muller Lorenz Chief Commercial Officer | Option exercise | 20.1K | — | — |
| 2026-01-26 | Nelson Jeffrey Edward Chief Operating Officer | Option exercise | 20.1K | — | — |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| RTW INVESTMENTS, LP | 7.5M | 6.3M |
| Propel Bio Management, LLC | 5.1M | 4.1M |
| TWO SIGMA INVESTMENTS, LP | 2.8M | 2.3M |
| GOLDMAN SACHS GROUP INC | 2.4M | 2.0M |
| MARSHALL WACE, LLP | 2.3M | 1.9M |
| MILLENNIUM MANAGEMENT LLC | 1.8M | 1.5M |
| Simplify Asset Management Inc. | 1.8M | 1.5M |
| Point72 Asset Management, L.P. | 1.3M | 1.1M |
| Balyasny Asset Management L.P. | 1.0M | 851.3K |
| Lion Point Capital, LP | 975.8K | 820.0K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 8-K | 2026-08-12 | 2026-08-12 | on EDGAR ↗ |
| 10-Q | 2026-08-12 | 2026-06-30 | on EDGAR ↗ |
| SCHEDULE 13G | 2026-08-07 | — | on EDGAR ↗ |
| 8-K | 2026-06-15 | 2026-06-10 | on EDGAR ↗ |
| 4 | 2026-06-12 | 2026-06-10 | on EDGAR ↗ |
| 4 | 2026-06-12 | 2026-06-10 | on EDGAR ↗ |
| 4 | 2026-06-12 | 2026-06-10 | on EDGAR ↗ |
| 4 | 2026-06-12 | 2026-06-10 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Milestone Pharmaceuticals stock gains on Phase 3 AFib trial · 2026-08-21
- Milestone Pharmaceuticals Inc. (MIST) filed form 8-K · 2026-08-12 · SEC EDGAR
- Milestone Pharmaceuticals Q2 2026 Earnings Preview · 2026-08-11
Ask the AI about MIST
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →